Huma Therapeutics acquired Aluna to expand its U.S. respiratory health footprint and integrate Aluna's remote monitoring platform into the Huma Cloud Platform.

A detailed report on Aluna's $15.3 million Series B funding round, including insights into the company's AI-enabled respiratory management platform, its growth strategy, and the impact of its technology on patient care for asthma, COPD, and cystic fibrosis.

Following the acquisition by Huma, Alcedis launched a dedicated U.S. respiratory clinical trial program leveraging Aluna's remote patient monitoring technology.

An overview of the acquisition of Aluna by Huma, detailing the strategic expansion of Huma's U.S. respiratory remote patient monitoring capabilities and the integration of Aluna's technology into the Huma Cloud Platform.